文献速递免疫规划卫生政策与健康促进

在九个非洲国家建立新冠疫苗主动安全性监测的经验教训

Lessons learnt during establishment of COVID-19 active vaccine safety surveillance in nine African countries.
PubMed 文献 · Vaccine · 2025-07-04

本报告介绍了在九个非洲国家建立两项医院哨点主动疫苗安全性监测研究:在八个COVAX AMC-92合格非洲国家开展的ACVaSS研究及南非的SA-CVSS研究,采用布莱顿协作病例定义对选定特殊关注不良事件进行分类。18个月内筛查超过60000名住院患者并纳入超过12700名合格患者,尽管纸质记录带来数据获取困难,但在中低收入国家医疗机构中识别特定AESI并估计其与疫苗接种状态的关联是可行的。

要点

  • 在九个非洲国家建立医院哨点主动疫苗安全性监测系统是可行的。
  • 18个月内筛查超过60000名住院患者,纳入超过12700名合格患者。
  • 纸质医疗和疫苗接种记录阻碍了数据的可及性和可用性。

核心结论

  • 在中低收入国家建立主动疫苗安全性监测哨点是可以实现的,但缺乏数字化医疗记录阻碍了数据的可及性和可用性。
  • 监管机构、卫生部门和资助免疫规划的组织必须优先发展、维护和资助主动疫苗安全性监测系统。

研究设计与样本

  • ACVaSS和SA-CVSS均为医院哨点主动监测研究,旨在监测新冠疫苗安全性。
  • ACVaSS在八个COVAX AMC-92合格非洲国家(埃塞俄比亚、加纳、肯尼亚、马里、马拉维、莫桑比克、尼日利亚和埃斯瓦蒂尼)开展,SA-CVSS在南非开展。
  • 因出现预选特殊关注不良事件(AESI)类似疾病就诊的患者经知情同意纳入研究,采用布莱顿协作病例定义对AESI进行分类。

主要发现

  • 18个月内筛查超过60000名住院患者,纳入超过12700名合格患者。
  • 尽管从以纸质为主的医疗和疫苗接种记录中获取和摘录数据存在挑战,但在中低收入国家医疗机构中识别特定AESI并估计其与疫苗接种状态的关联是可行的。

临床怎么用

  • 监管机构、卫生部门和资助免疫规划的组织必须优先发展、维护和资助主动疫苗安全性监测系统。
  • 此类监测对于确保新疫苗在这些人群中引入和使用后得到适当监测和安全性评估至关重要。

局限性

  • 这些国家通常依赖纸质医疗记录和免疫接种卡,医疗系统缺乏唯一患者标识符,电子数据采集能力有限,且病例评估的临床审查人员短缺。
  • 缺乏数字化医疗记录阻碍了数据的可及性和可用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Globally, several gaps in vaccine safety surveillance exist, particularly in low- and middle- income countries (LMICs). Establishing and maintaining vaccine surveillance platforms in resource-constrained settings poses significant challenges. These countries often rely on paper-based medical records and immunization cards, lack unique patient identifiers across the healthcare systems, have limited electronic data capture capabilities, and face a shortage of clinical reviewers for case assessments. This report highlights the establishment of two active vaccine safety surveillance studies across nine African countries: (i) Active COVID-19 vaccine safety surveillance (ACVaSS) in eight COVAX 92 Advanced Market Commitment (AMC-92) eligible African countries including Ethiopia, Ghana, Kenya, Mali, Malawi, Mozambique, Nigeria and Eswatini and (ii) the South African COVID-19 vaccine safety surveillance study (SA-CVSS). METHODS: Both ACVaSS and SA-CVSS were hospital-based sentinel active surveillance studies designed to monitor the safety of COVID-19 vaccines in the aforementioned COVAX AMC-92 countries and South Africa, a middle-income African country. Patients presenting to healthcare facilities with illnesses resembling pre-selected adverse events of special interest (AESIs), were enrolled, with informed consent, into the studies. The Brighton Collaboration Case Definitions were applied to classify AESIs. FINDINGS: Over 60,000 admitted patients were screened and over 12,700 eligible patients were enrolled in 18 months. Despite challenges in accessing and abstracting data from predominantly paper-based medical and vaccination records, the identification of specific AESIs and estimating association with vaccination status was feasible in LMIC healthcare facilities. CONCLUSIONS: The establishment of active vaccine safety surveillance sentinel sites is achievable in LMICs, though the lack of digital medical records hindered data accessibility and availability. Regulatory authorities, health departments and organizations supporting immunization programs must prioritize the development, maintenance and funding of active vaccine safety surveillance systems. Such surveillance is crucial to ensuring that new vaccines are properly monitored and assessed for safety following their introduction and use in these populations. FUNDING: The SA-CVSS study was funded by a US CDC Grant to the GVDN (grant reference: CDC Funder Award Number: 1 NU38CK000485-01-00), the South African Medical Research Council (SAMRC) and the Task Force for Global Health (RVD_CDC-COV). Gavi, The Vaccine Alliance, funded the ACVaSS study (Agreement reference: MEL10500921).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cutland CL, Gutu K, Yun JA, et al. Lessons learnt during establishment of COVID-19 active vaccine safety surveillance in nine African countries. Vaccine. 2025. PMID: 40617089. doi:10.1016/j.vaccine.2025.127441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。